Validity and security of leveraging CS1 chimeric antigen receptor T-cell therapy treating relapsed/ refractory/ high risk CS1+ hematological malignancy: a single-center, open, single-arm clinical study
Latest Information Update: 03 Jan 2018
At a glance
- Drugs CD319-chimeric-antigen-T-cell-therapy-Wuhan-Bio-Raid-Biotechnology (Primary)
- Indications Haematological malignancies
- Focus Therapeutic Use
- 03 Jan 2018 New trial record